Journal
Calcified tissue international
Publication Date
5-1-2021
Volume
108
Issue
5
First Page
622
Last Page
633
Document Type
Open Access Publication
DOI
10.1007/s00223-020-00797-x
Rights and Permissions
Padidela, R., Whyte, M.P., Glorieux, F.H. et al. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int 108, 622–633 (2021). https://doi.org/10.1007/s00223-020-00797-x This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Padidela, Raja; Whyte, Michael P; and et al., "Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia." Calcified tissue international. 108, 5. 622 - 633. (2021).
https://digitalcommons.wustl.edu/oa_4/1169
Additional Links
Supplemental material is available for this article at publisher site.
